Phytochemical Name : Mistletoe extract (PS76A2)

Properties Information
PhytoCAT-ID PhytoCAT-1496
Phytochemical name or plant extracts Mistletoe extract (PS76A2)
PMID 15154663
Literature evidence The standardised mistletoe extract PS76A2 improves QoL in patients with breast cancer receiving adjuvant CMF chemotherapy: a randomised, placebo-controlled, double-blind, multicentre clinical trial.
IUPAC name NA
Phytochemicals’ class or type of plant extracts Aqueous extract
Source of phytochemicals or plant Extracts Viscum album
Geographical availability Albania, Algeria, Austria, Baleares, Baltic States, Belarus, Belgium, Bulgaria, Central European Rus, China South-Central, Corse, Czechoslovakia, Denmark, East European Russia, East Himalaya, France, Germany, Great Britain, Greece, Hungary, Iran, Italy, Kriti, Krym, Lebanon-Syria, Morocco, Myanmar, Nepal, Netherlands, North Caucasus, Northwest European R, Norway, Pakistan, Poland, Portugal, Romania, Sicilia, South European Russi, Spain, Sweden, Switzerland, Tibet, Transcaucasus, Turkey, Turkey-in-Europe, Ukraine, Vietnam, West Himalaya, Yugoslavia
Plant parts NA
Other cancers Breast cancer, Skin cancer, Myosarcoma, Colon cancer
Target gene or protein TNF, H2A histone family member X, Plasminogen
Gene or Protein evidence Simultaneous treatment of human cervix carcinoma HeLa or breast carcinoma MCF-7 cells with MLs isolated from European or Korean mistletoe rendered them more sensitive to induction of apoptosis by TNF. In all supernatants of AM-stimulated cell culture TNF-alpha and IL-6 were found, Indicating activation of cells of the monocyte/macrophage lineage by mistletoe extracts. Mistletoe extract simultaneously increased the expression of the DNA damage marker proteins, phosphorylated H2A histone family member X (H2A.X), and phosphorylated p38.In addition to tumor growth inhibition, mistletoe extract inhibited lung metastasis in the tumor-bearing mice and cell invasiveness by downregulating the expressions of matrix metalloproteinases (MMPs), urokinase-type plasminogen activator (uPA), uPA receptor, and markers of epithelial-mesenchymal transition (snail and fibronectin).
Target pathways Mistletoe extract targets the STAT3-FOXM1 pathway for its cytotoxic effect.
IC50 NA
Potency Quality of life is improved in breast cancer patients by Standardised Mistletoe Extract PS76A2 during chemotherapy and follow-up: a randomised, placebo-controlled, double-blind, multicentre clinical trial.
Cell line/ mice model MCF-7, HT-144, SK-MEL-28, SK-MLS-1, S-UT-1B, Kpl-1, Mfm-223
Additional information  Therefore, the objective of this clinical study was to investigate the impact of PS76A2, an aqueous mistletoe extract standardised to the galactoside-specific mistletoe lectin, on QoL by performing a placebo-controlled trial. As a result, statistically significant effects on QoL were obtained with the medium dose (15 ng ML/0.5 ml). The treatment difference between the medium dose and placebo with regard to the GLQ-8 sum was 60.8 mm (95% confidence interval: 19.3 to 102.0 mm). The treatment effect for Spitzer's uniscale between the medium dose and placebo was 16.4 mm (95% confidence interval: 6.3 to 26.6 mm). The results on QoL were supported by an increase of T helper lymphocytes (CD4+) and the CD4+/CD8+ ratio (p<0.05). Overall, PS76A2 was well tolerated. Local reactions at the injection sites occurred dose-dependently, but were mild at the low and medium dose levels.
PubChem ID NA
Additional PMIDs 15219134 15154645 14981970 15154663 15353899 14666680 16927530 16619567 21289969 16927532 17695469 18383896 21556248 19295230 33622211 8067703 9010693 9533928 24876872
Additional sources of information https://powo.science.kew.org/taxon/urn:lsid:ipni.org:names:300881-2
Safety NA